Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Sitagliptin
Generic Name
Sitagliptin
Active Ingredient
SitagliptinCategory
Dipeptidyl Peptidase 4 Inhibitor [EPC]
Salt Form
Phosphate
Variants
6
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 25 mg/1 | TABLET | ORAL | 70710-1899 |
| 100 mg/1 | TABLET | ORAL | 70771-1792 |
| 50 mg/1 | TABLET | ORAL | 70710-1900 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sitagliptin, you must consult a qualified healthcare professional.
| 50 mg/1 | TABLET | ORAL | 70771-1791 |
| 100 mg/1 | TABLET | ORAL | 70710-1901 |
| 25 mg/1 | TABLET | ORAL | 70771-1790 |
Detailed information about Sitagliptin
Sitagliptin is a Dipeptidyl Peptidase 4 (DPP-4) inhibitor used to improve blood sugar control in adults with type 2 diabetes mellitus. It works by increasing levels of natural substances called incretins, which help control blood sugar by increasing insulin release.
The standard recommended dose of sitagliptin for adults with type 2 diabetes is 100 mg taken once daily. This dose can be taken with or without food. Healthcare providers often prescribe sitagliptin as part of a comprehensive management plan that includes medical nutrition therapy (diet) and physical activity. While 100 mg is the standard, the dose must be individualized based on the patient's renal function to ensure safety and efficacy.
As of 2024, the safety and effectiveness of sitagliptin in pediatric patients under the age of 18 have not been established. Clinical trials in pediatric populations have been conducted, but sitagliptin is currently not FDA-approved for use in children or adolescents. Parents and caregivers should consult a pediatric endocrinologist for appropriate management strategies for type 2 diabetes in younger populations.
Because sitagliptin is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with impaired renal function. Healthcare providers will typically perform a blood test to measure the estimated Glomerular Filtration Rate (eGFR) or Creatinine Clearance (CrCl) before starting treatment and periodically thereafter.
No dosage adjustment is necessary for patients with mild to moderate hepatic (liver) impairment (Child-Pugh score 7 to 9). Sitagliptin has not been studied in patients with severe hepatic impairment, so caution is advised in this population.
No specific dosage adjustment is required based solely on age. However, since elderly patients are more likely to have decreased renal function, dose selection should be based on renal status. Clinical studies have shown that sitagliptin is generally well-tolerated in patients aged 65 and older.
If you miss a dose of sitagliptin, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at the same time to make up for a missed one, as this increases the risk of side effects.
In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. While sitagliptin has a high safety margin, excessive amounts may lead to complications. In clinical trials, single doses of up to 800 mg were generally well-tolerated, but standard supportive measures (such as removing unabsorbed material from the gastrointestinal tract and clinical monitoring) should be employed in an overdose scenario. Sitagliptin is modestly dialyzable (about 13.5% over a 4-hour session).
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to a dangerous spike in blood sugar levels.
Most patients tolerate sitagliptin well; however, some common side effects may occur as the body adjusts to the medication. These are generally mild and may include:
Some patients may experience gastrointestinal or systemic symptoms, including:
Sitagliptin is a potent medication that requires careful medical supervision. It is not for everyone, and certain pre-existing conditions can increase the risk of severe complications. Patients must be aware of the signs of pancreatitis and heart failure, as these are the most critical safety concerns associated with the DPP-4 inhibitor class.
No FDA black box warnings for Sitagliptin. While it lacks the most severe level of FDA warning, this does not mean the drug is without risk. The precautions regarding the pancreas and kidneys are significant and must be respected.
There have been post-marketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking sitagliptin. It is unknown whether patients with a history of pancreatitis are at increased risk. If you have ever had pancreatitis, gallstones, a history of alcoholism, or high triglyceride levels, discuss these with your doctor before starting sitagliptin.
There are no drugs that are strictly contraindicated (forbidden) for use with sitagliptin based on direct chemical interactions. However, sitagliptin should never be used in patients who have had a previous serious hypersensitivity reaction to it. Additionally, using sitagliptin with other DPP-4 inhibitors (e.g., saxagliptin, linagliptin) is not recommended as it provides no additional benefit and increases the risk of side effects.
Sitagliptin must NEVER be used in the following circumstances:
Sitagliptin is classified as Pregnancy Category B (under the older FDA system). This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.
It is not known whether sitagliptin is excreted in human milk. In animal studies (rats), sitagliptin was secreted in milk. Because many drugs are excreted in human milk, caution should be exercised when sitagliptin is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for sitagliptin and any potential adverse effects on the breastfed infant.
Sitagliptin is a competitive inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme is responsible for the rapid degradation of incretin hormones, specifically Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). These hormones are released by the gut in response to food intake and play a vital role in glucose homeostasis.
By inhibiting DPP-4, sitagliptin increases the levels of active GLP-1 and GIP. This results in:
Common questions about Sitagliptin
Sitagliptin is a prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It is used as an adjunct to diet and exercise to lower hemoglobin A1c levels and prevent the long-term complications of diabetes. It works by inhibiting the DPP-4 enzyme, which increases the levels of natural hormones that stimulate insulin production. Sitagliptin is not for people with type 1 diabetes or those with diabetic ketoacidosis. It can be used alone or in combination with other diabetes medications like metformin or insulin.
The most common side effects of sitagliptin include upper respiratory tract infections, such as the common cold, sore throat, and runny nose. Some patients also report headaches and nasopharyngitis. If taken with other medications like metformin, gastrointestinal issues such as diarrhea or upset stomach may occur. While generally well-tolerated, it is important to monitor for any new or worsening symptoms. Most mild side effects resolve as the body becomes accustomed to the medication.
You should exercise caution when consuming alcohol while taking sitagliptin. Alcohol can increase the risk of hypoglycemia (low blood sugar) and may also increase the risk of developing pancreatitis, a serious inflammation of the pancreas. Chronic or excessive alcohol use can also make it more difficult to manage your diabetes effectively. It is best to discuss your alcohol consumption with your healthcare provider to determine a safe amount for your specific health situation. Always avoid drinking alcohol on an empty stomach if you are on diabetes medication.
Sitagliptin is generally not the first choice for managing diabetes during pregnancy. While animal studies have not shown direct harm to the fetus, there is insufficient data from human studies to guarantee its safety. Most healthcare providers prefer to use insulin to manage blood sugar during pregnancy because it has a long-established safety profile for both the mother and the baby. If you are pregnant or planning to become pregnant, you should talk to your doctor about transitioning to a different treatment. Controlling blood sugar is vital during pregnancy to prevent birth defects and other complications.
Sitagliptin begins to inhibit the DPP-4 enzyme within a few hours of the first dose, leading to improved insulin response after your next meal. However, it may take several days or even weeks of consistent use to see a significant drop in your daily fasting blood sugar levels. The full effect on your HbA1c (a 3-month average of blood sugar) is typically evaluated after 3 to 6 months of continuous therapy. It is important to take the medication every day as prescribed, even if you do not feel an immediate difference in your symptoms. Consistency is key to achieving long-term glycemic control.
You should never stop taking sitagliptin suddenly without first consulting your healthcare provider. Stopping the medication can cause your blood sugar levels to rise, which may lead to symptoms of hyperglycemia like increased thirst and frequent urination. Over time, high blood sugar increases the risk of serious complications such as heart disease, kidney damage, and vision loss. If you need to stop the medication due to side effects, your doctor will help you transition to an alternative treatment safely. Always maintain open communication with your medical team regarding your treatment plan.
If you miss a dose of sitagliptin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at once to make up for a missed one, as this could potentially lead to side effects or an unexpected drop in blood sugar. Keeping your medication in a pill organizer or setting a daily alarm can help you remember to take it consistently. If you frequently miss doses, discuss strategies with your pharmacist or doctor.
Sitagliptin is generally considered to be 'weight-neutral,' meaning it typically does not cause weight gain or weight loss in most patients. This is a significant advantage over some other diabetes medications, such as sulfonylureas or insulin, which are often associated with weight gain. Because sitagliptin works in a glucose-dependent manner and does not cause significant hypoglycemia, it does not usually lead to the increased calorie consumption that sometimes follows low blood sugar episodes. Maintaining a healthy diet and exercise routine remains important for overall diabetes management while taking this drug.
Yes, sitagliptin is frequently prescribed in combination with other diabetes medications like metformin, pioglitazone, or insulin. However, it can interact with certain drugs, such as digoxin, potentially increasing its levels in your blood. When taken with insulin or sulfonylureas, the risk of hypoglycemia is higher, and your doctor may need to adjust the doses of those medications. Always provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are taking. This allows them to screen for potential interactions and ensure your treatment is safe.
Yes, sitagliptin is available as a generic medication in many regions, including the United States. Generic sitagliptin contains the same active ingredient as the brand-name version (Januvia) and meets the same FDA standards for quality, strength, and purity. Choosing the generic version can often significantly reduce the out-of-pocket cost for patients. If you are interested in switching to the generic form, talk to your pharmacist or healthcare provider to ensure you receive the correct dosage. Availability may vary depending on your local pharmacy and insurance coverage.
Other drugs with the same active ingredient (Sitagliptin)
> Warning: Stop taking Sitagliptin and call your doctor immediately if you experience any of these serious conditions:
Long-term use of sitagliptin is generally considered safe based on cardiovascular outcome trials like the TECOS study (2015), which followed over 14,000 patients for an average of 3 years. The study found no increased risk of major adverse cardiovascular events. However, long-term monitoring for renal function and skin integrity is recommended, as rare conditions like bullous pemphigoid may take time to manifest.
As of the latest FDA updates in 2024, there are no FDA black box warnings for sitagliptin. However, the warnings regarding pancreatitis and heart failure are considered high-priority precautions that healthcare providers must discuss with patients before initiating therapy.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular follow-up appointments are essential to monitor for both the efficacy of the drug and the presence of any underlying side effects.
An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for other members of the drug class. While the TECOS trial for sitagliptin did not show a statistically significant increase in heart failure hospitalizations, patients with a history of heart or kidney disease should be monitored closely for signs such as edema and dyspnea (shortness of breath).
Sitagliptin is renally excreted. To avoid excessive accumulation of the drug, dosage adjustments are required in patients with moderate to severe renal insufficiency. There have been reports of acute renal failure in patients taking sitagliptin, sometimes in those who were already at risk for kidney problems.
Serious hypersensitivity reactions have occurred. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. These reactions typically occur within the first 3 months after initiation of treatment, but can occur after the first dose.
To ensure the safe use of sitagliptin, healthcare providers will typically order the following tests:
Sitagliptin itself is unlikely to affect your ability to drive or use machines. However, if you are taking it with other diabetes medications (like insulin or sulfonylureas), your blood sugar could drop too low (hypoglycemia). Hypoglycemia can cause dizziness, blurred vision, and impaired concentration. Do not drive or operate heavy machinery until you know how sitagliptin affects your blood sugar levels.
Alcohol can interfere with blood sugar control and increase the risk of both hypoglycemia and pancreatitis. Excessive alcohol consumption should be avoided while taking sitagliptin. Discuss your alcohol intake habits with your healthcare provider to determine what is safe for you.
Do not stop taking sitagliptin suddenly without consulting your doctor. Stopping the medication can cause your blood sugar levels to rise rapidly (hyperglycemia), which increases the risk of long-term diabetes complications like nerve damage, kidney failure, and vision loss. There is no known withdrawal syndrome, but blood sugar must be managed through alternative means if sitagliptin is discontinued.
> Important: Discuss all your medical conditions, especially any history of kidney disease, heart failure, or pancreas problems, with your healthcare provider before starting Sitagliptin.
Sitagliptin does not have significant interactions with specific foods. It can be taken with or without food. Unlike some other medications, it does not interact with grapefruit juice or dairy products. However, maintaining a consistent carbohydrate-controlled diet is essential for the medication to work effectively.
Sitagliptin is not known to interfere with common laboratory tests. However, it will lower your HbA1c and blood glucose readings, which is the intended therapeutic effect. Always inform laboratory personnel and your doctors of all medications you are taking.
For each major interaction, the primary concern is either the management of blood glucose levels (preventing hypoglycemia) or the preservation of renal function. Because sitagliptin is primarily cleared by the kidneys, any drug that significantly impairs kidney function (such as high-dose NSAIDs like ibuprofen or certain antibiotics) can indirectly increase sitagliptin levels in the body.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs and vitamins.
While not extensively documented, there is a theoretical risk of cross-sensitivity between different DPP-4 inhibitors. If a patient has had a serious allergic reaction to another 'gliptin' (such as linagliptin or saxagliptin), healthcare providers should exercise extreme caution or avoid sitagliptin altogether. There is no known cross-sensitivity between sitagliptin and other classes of diabetes drugs like metformin or SGLT2 inhibitors.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies and your kidney health, before prescribing Sitagliptin.
Sitagliptin is not approved for use in patients under 18 years of age. While type 2 diabetes is becoming more common in adolescents, the long-term effects of DPP-4 inhibition on growth and development are not fully understood. Clinical trials in this age group have not yet resulted in an FDA-approved indication.
In clinical studies, no overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects. However, because sitagliptin is substantially excreted by the kidney, and because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Renal function should be monitored more frequently in this population to prevent drug accumulation.
Renal impairment is the most significant factor in sitagliptin dosing.
Patients on dialysis can take sitagliptin, and the dose can be given regardless of the timing of the dialysis session.
No dosage adjustment is required for mild to moderate hepatic impairment. For patients with severe hepatic impairment, the pharmacokinetics of sitagliptin have not been established. In such cases, healthcare providers must weigh the benefits against the unknown risks of altered drug metabolism.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or if you are over the age of 65.
| Parameter | Value |
|---|---|
| Bioavailability | ~87% |
| Protein Binding | ~38% |
| Half-life | ~12.4 hours |
| Tmax | 1 to 4 hours |
| Metabolism | Minor (CYP3A4, CYP2C8) |
| Excretion | Renal 87%, Fecal 13% |
Sitagliptin is the first-in-class Dipeptidyl Peptidase 4 (DPP-4) inhibitor. It is classified as an antihyperglycemic agent. Other drugs in this class include Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina). Unlike GLP-1 receptor agonists (like Ozempic), which mimic the hormone, sitagliptin preserves the body's own natural hormones.